Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterby Chloe I Bloom, et. al.,
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19by Ryan S Thwaites, et. al.,
What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic reviewby Melina Michelen, et. al.
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trialby Wang, Y., Zhou, F., Zhang, D. et al.
Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid reviewby Andrew Dagens, Louise Sigfrid, Erhui Cai, Sam Lipworth, Vincent Cheung, Eli Harris, Peter Bannister, Ishmeala Rigby, Peter Horby
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort studyby ISARIC
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialby Yeming Wang MD, Dingyu Zhang MD, Prof Guanhua Du PhD, Prof Roghui Du MD, Prof Jianping Zhao MD, Prof Yang Jin MD
The Lancet - 29th April 2020 No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. Read full article